VCBeat Health Contact Us
Home After the $2.75B Deals: How AI Biotechs Are Turning 'Shovels' into Real Gold – Answers from Suzhou

After the $2.75B Deals: How AI Biotechs Are Turning 'Shovels' into Real Gold – Answers from Suzhou

Jun 24, 2026 09:55 CST Updated 09:55
Sanofi

Pharmaceutical Manufacturer

Helixon

AI Technology New Drug Developer

XtalPi

Computation-Driven Innovative Drug R&D Provider

SIGNET

Innovative Targeted Cancer Drug Developer

Image

In spring 2026, Insilico Medicine and Eli Lilly reached a deal with a maximum value of approximately$2.75 billionof external licensing and global R&D collaborations.

In the same month, Sanofi signed$2.56 billion...collaboration with Helixon.
Received by XtalPi$19 millionMilestone payment: the project has successfully entered the IND-enabling stage.

If you are the founder or head of R&D at an AI biotech company, you will inevitably ask:

  • Behind these deals, what exactly are MNCs looking for? Is it model accuracy, or developability?
  • When will my AI platform also be able to develop such assets?
  • Where did those failed collaborations stall—CMC, regulatory affairs, or clinical data?

We have incorporated the answers to all these questions into the conference held in Suzhou on September 5.

Conference Theme:“Leveraging the New Shovel: Dual-Track Practice of Macromolecular AI from Model Capabilities to Clinical Validation and BD Realization”
No discussion of algorithmic principles, onlyReal-World Pitfalls and Validation Pathways。
Section 1: Speed Shovel · Seizing Time Amidst Certainty
PCC-to-IND Acceleration
AI + Organoids/Automated Experiments: How to Truly Compress Timelines?
Cross-Modal DMTA Decision-Making
For the Same Target, How to Select and Promote Bispecific Antibodies, ADCs, and Nucleic Acid Therapeutics?
Developability First
How Macromolecule Design Bridges the CMC and Manufacturing Divide to Support Major BD Deals?
Section II: Precision Shovel · Finding Answers in Uncharted Territory
Breaking Through the Barrier of Undruggable Targets
From 0 to 1 FIC: AI-Driven Target Discovery and Precision Design of Bispecific/Multispecific Antibodies
AI × Nucleic Acid Delivery
mRNA/siRNA Sequence Optimization, Vector Design, and In Vivo Data Decay Correction
AI×CGT: Avoiding Pitfalls
Eliminating False Positives in CAR-T Targets, Mitigating Cross-Species Attenuation of AAV, and De-risking Off-Target Effects in Gene Editing
AI × Antibody
Can high affinity, low immunogenicity, and developability be simultaneously achieved?
AI × Delivery
From LNPs to Complex Formulations: Precision Targeted Delivery of Macromolecular Drugs
Section 3: Dual Capabilities · Manufacturable, Scalable, Marketable
Deliverable (ROI Realization)
The Real Accounting Logic and Milestone Value Realization of AI-Driven CMC for Cost Reduction and Efficiency Enhancement
Approval Granted (Compliance Baseline)
Navigating New NMPA/EMA Regulations: Explainability of AI Outputs, Audit Trails, and Submission Approval Strategies
Sellable (Decision Endgame)
AI-Driven Clinical Trial Design and Patient Stratification: Can They Truly Reshape the Final Decision-Making Landscape?
Proposed Guests (Partial)

▪HelixonFounder and CEO, Peng Jian
▪SIGNETFounder/CEO Zhang Haisheng
▪XtalPi / Insilico MedicineProject Leader
▪Ribo Life Science / Yaotang BiopharmaHead of R&D
▪Leman BioTechnical Director
▪Innovent BiologicsHead of AI Antibody Platform
▪Jitai TechnologyCEO Lai Caida
▪MegaRobo / ChemPartnerCMC Expert
▪NMPA Review Expert
▪Innovent BiologicsFounder/CEO Dr. Dechao Yu
▪ AstraZenecaGlobal Executive Vice President Wang Lei and other industry leaders

This is not an “AI worship session,” but an “AI practical review meeting.”
Every speaker we have invited isIndividuals who have previously excavated minerals using shovels—Regardless of whether the mining operation is large or small, they at least know which pitfalls they have encountered.

Time:September 5, 2026 (Saturday) 9:30-17:00
Location:Suzhou International Expo Center · Biological Drug Exhibition Hall B108
Scale:150-200 people

Who Should Attend?
  • Head of R&D for Large-Molecule Drugs (Antibodies, Nucleic Acids, CGT)
  • CEO/CSO/CTO of AI Pharmaceutical Company
  • Decision-Makers in Business Development (BD), Chemistry, Manufacturing and Controls (CMC), and Clinical Registration at Pharmaceutical Companies
  • Investors seeking to validate whether “the AI shovel” is a worthwhile investment
Image

↑↑↑ Scan the QR code to register now ↑↑↑

YiQi AI Intelligent Transformation Conference (East China) · Organizing Committee